6cup - Revision history

OCA at 15:11, 4 October 2023

2023-10-04T15:11:29Z

←Older revision		Revision as of 15:11, 4 October 2023
Line 1:		Line 1:

-	====	+	==Ras:SOS:Ras in complex with a small molecule activator==
-	<StructureSection load='6cup' size='340' side='right'caption='[[6cup]]' scene=''>	+	<StructureSection load='6cup' size='340' side='right'caption='[[6cup]], [[Resolution\|resolution]] 1.83Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6cup]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6CUP OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6CUP FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6cup FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6cup OCA], [https://pdbe.org/6cup PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6cup RCSB], [https://www.ebi.ac.uk/pdbsum/6cup PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6cup ProSAT]</span></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.833Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CSO:S-HYDROXYCYSTEINE'>CSO</scene>, <scene name='pdbligand=FFV:N~2~-(3-chloro-4-fluorophenyl)-N~4~-[(1R)-1-cyclopropylethyl]quinazoline-2,4-diamine'>FFV</scene>, <scene name='pdbligand=FMT:FORMIC+ACID'>FMT</scene>, <scene name='pdbligand=GNP:PHOSPHOAMINOPHOSPHONIC+ACID-GUANYLATE+ESTER'>GNP</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6cup FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6cup OCA], [https://pdbe.org/6cup PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6cup RCSB], [https://www.ebi.ac.uk/pdbsum/6cup PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6cup ProSAT]</span></td></tr>
	</table>		</table>
		+	== Disease ==
		+	[https://www.uniprot.org/uniprot/RASH_HUMAN RASH_HUMAN] Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:[https://omim.org/entry/218040 218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.<ref>PMID:16170316</ref> <ref>PMID:16329078</ref> <ref>PMID:16443854</ref> <ref>PMID:17054105</ref> <ref>PMID:18247425</ref> <ref>PMID:18039947</ref> <ref>PMID:19995790</ref> Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:[https://omim.org/entry/218040 218040]. CMEMS is a variant of Costello syndrome.<ref>PMID:17412879</ref> Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:[https://omim.org/entry/607464 607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms. Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:[https://omim.org/entry/109800 109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).<ref>PMID:1459726</ref> Defects in HRAS are the cause of Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:[https://omim.org/entry/163200 163200]. A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis.<ref>PMID:22683711</ref>
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/RASH_HUMAN RASH_HUMAN] Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.<ref>PMID:14500341</ref> <ref>PMID:9020151</ref> <ref>PMID:12740440</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Proteins in the RAS family are important regulators of cellular signaling and, when mutated, can drive cancer pathogenesis. Despite considerable effort over the last 30 years, RAS proteins have proven to be recalcitrant therapeutic targets. One approach for modulating RAS signaling is to target proteins that interact with RAS, such as the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 (SOS1). Here, we report hit-to-lead studies on quinazoline-containing compounds that bind to SOS1 and activate nucleotide exchange on RAS. Using structure-based design, we refined the substituents attached to the quinazoline nucleus and built in additional interactions not present in the initial HTS hit. Optimized compounds activate nucleotide exchange at single-digit micromolar concentrations in vitro. In HeLa cells, these quinazolines increase the levels of RAS-GTP and cause signaling changes in the mitogen-activated protein kinase/extracellular regulated kinase (MAPK/ERK) pathway.
		+
		+	Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS.,Abbott JR, Patel PA, Howes JE, Akan DT, Kennedy JP, Burns MC, Browning CF, Sun Q, Rossanese OW, Phan J, Waterson AG, Fesik SW ACS Med Chem Lett. 2018 Aug 8;9(9):941-946. doi: 10.1021/acsmedchemlett.8b00296. , eCollection 2018 Sep 13. PMID:30258545<ref>PMID:30258545</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 6cup" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[GTPase Hras 3D structures\|GTPase Hras 3D structures]]
		+	*[[Son of sevenless\|Son of sevenless]]
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: ~~Z-disk~~]]	+	[[Category: Abbott J]]
		+	[[Category: Fesik SW]]
		+	[[Category: Phan J]]

OCA at 10:17, 18 March 2021

2021-03-18T10:17:09Z

←Older revision		Revision as of 10:17, 18 March 2021
Line 3:		Line 3:
	<StructureSection load='6cup' size='340' side='right'caption='[[6cup]]' scene=''>		<StructureSection load='6cup' size='340' side='right'caption='[[6cup]]' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>	+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=6cup FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6cup OCA], [~~http~~://pdbe.org/6cup PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6cup RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6cup PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6cup ProSAT]</span></td></tr>	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6cup FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6cup OCA], [https://pdbe.org/6cup PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6cup RCSB], [https://www.ebi.ac.uk/pdbsum/6cup PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6cup ProSAT]</span></td></tr>
	</table>		</table>
	__TOC__		__TOC__

OCA at 09:01, 11 November 2020

2020-11-11T09:01:18Z

←Older revision		Revision as of 09:01, 11 November 2020
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6cup ~~is ON HOLD until Paper Publication~~	+	====
-		+	<StructureSection load='6cup' size='340' side='right'caption='[[6cup]]' scene=''>
-	~~Authors~~: ~~Phan, J~~.~~, Abbott, J~~.~~, Fesik, S~~.W.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>
-	~~Description~~: ~~Ras~~:~~SOS~~:~~Ras in complex with a small molecule activator~~	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6cup FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6cup OCA], [http://pdbe.org/6cup PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6cup RCSB], [http://www.ebi.ac.uk/pdbsum/6cup PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6cup ProSAT]</span></td></tr>
-	[[~~Category~~: ~~Unreleased Structures~~]]	+	</table>
-	[~~[Category~~: ~~Phan~~, J]]	+	__TOC__
-	[[Category: ~~Fesik, S.W~~]]	+	</StructureSection>
-	[[Category: ~~Abbott, J~~]]	+	[[Category: Large Structures]]
		+	[[Category: Z-disk]]

OCA at 12:26, 11 April 2018

2018-04-11T12:26:39Z

←Older revision		Revision as of 12:26, 11 April 2018
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6cup is ON HOLD	+	The entry 6cup is ON HOLD until Paper Publication

	Authors: Phan, J., Abbott, J., Fesik, S.W.		Authors: Phan, J., Abbott, J., Fesik, S.W.

OCA: Protected "6cup" [edit=sysop:move=sysop]

2018-04-04T04:42:56Z

Protected "6cup" [edit=sysop:move=sysop]

←Older revision

Revision as of 04:42, 4 April 2018

OCA: New page: '''Unreleased structure''' The entry 6cup is ON HOLD Authors: Phan, J., Abbott, J., Fesik, S.W. Description: Ras:SOS:Ras in complex with a small molecule activator [[Category: Unreleas...

2018-04-04T04:42:54Z

New page: '''Unreleased structure''' The entry 6cup is ON HOLD Authors: Phan, J., Abbott, J., Fesik, S.W. Description: Ras:SOS:Ras in complex with a small molecule activator [[Category: Unreleas...

New page

'''Unreleased structure'''

The entry 6cup is ON HOLD

Authors: Phan, J., Abbott, J., Fesik, S.W.

Description: Ras:SOS:Ras in complex with a small molecule activator
[[Category: Unreleased Structures]]
[[Category: Phan, J]]
[[Category: Fesik, S.W]]
[[Category: Abbott, J]]